Off the scales : the inside story of Ozempic and the race to cure obesity.
Record details
- ISBN: 9781250389060
- Physical Description: 305 pages ; 23 cm
- Publisher: New York (State) : St. Martin's Publishing Group, 2025.
Content descriptions
| General Note: | CO |
| Immediate Source of Acquisition Note: | Library Bound Incorporated |
Search for related items by subject
| Subject: | BUSINESS & ECONOMICS / Industries / Pharmaceutical & Biotechnology HEALTH & FITNESS / Diet & Nutrition / Weight Loss MEDICAL / Clinical Medicine SOCIAL SCIENCE / Disease & Health Issues |
Available copies
- 0 of 1 copy available at Tsuga Consortium.
Holds
- 0 current holds with 1 total copy.
| Location | Call Number / Copy Notes | Barcode | Shelving Location | Status | Due Date |
|---|---|---|---|---|---|
| Cookstown Branch | ON ORDER | pr08000405 | NONFIC | On order | - |
- Baker & Taylor
"The inside story of the race to develop Ozempic, and its potentially revolutionary impact on public health and culture. A "cure" for obesity has long been the holy grail for the pharmaceutical industry, one that seemed unattainable until recent breakthroughs in type 2 diabetes research led to the development of Ozempic, a weight loss medication that activates hormones in the stomach, making people feel fuller for longer. The treatment is so effective that it is already disrupting many industries-from healthcare to fast food to fashion-and it has quickly made its creator, Denmark's Novo Nordisk, the most valuable company in Europe. But the impact of these drugs goes far beyond billion-dollar profits; a true long-term cure for obesity could save 40% of American adults from dangerous preventable illnesses. And as their success continues to grow, one question looms in the minds of investors, healthcare workers and politicians: are they too good to be true? In Off the Scales, Reuters journalist Aimee Donnellan illuminates the history of the latest medical breakthrough that is poised to change the world, while bringing difficult social questions about inequality and morality to the forefront. Through original reporting and rigorous research, she forecasts thefuture of Ozempic and similar medications-and examines what their explosive popularity tells us about our ideals of beauty, the lengths to which people will go in order to become thin, the current state of healthcare, and the inner workings of the pharmaceutical industry. Along the way, Donnellan profiles the scientist whose contributions to the discovery of GLP-1 were overlooked and her fight for recognition while her colleagues were thrust into the limelight, and offers new insights into the ways that the food and beauty industries made billions while promoting unhealthy and unrealistic body image standards and accelerating the obesity crisis. She also reveals the lengths that the celebrity class went to obtain this medication when supplies were limited and prescriptions were costly, and relates the first-hand accounts of several early Ozempic users and the transformative effect the drug has had on their weight loss journeys. Above all, Off the Scales is an informative and entertaining study of the unexpected social consequences of finally getting what we've wanted for so long"-- Provided by publisher. - McMillan Palgrave
The inside story of the creation of Ozempic and its revolutionary impact on public health.
A âcureâ for obesity has long been the holy grail for the pharmaceutical industry, one that seemed unattainable until recent breakthroughs in type 2 diabetes research led to the development of Ozempic, a weight loss medication that activates a hormone in the stomach called GLP-1, making people feel fuller for longer. The treatment is so effective that it is already disrupting many industriesâfrom healthcare to fast food to fashionâand it has quickly made its creator, Denmarkâs Novo Nordisk, the most valuable company in Europe. But the impact of GLP-1s goes far beyond billion-dollar profits; a true long-term cure for obesity could save 40 percent of American adults from dangerous, preventable illnesses. And as more potential benefits emerge, one question looms in the minds of investors, healthcare workers, and politicians: Are these drugs too good to be true?
In Off the Scales, Reuters journalist Aimee Donnellan illuminates the history of a medical breakthrough that is poised to change the world, while raising difficult social questions about inequality and morality. Through original reporting and rigorous research, she forecasts the future of GLP-1s and examines what their explosive popularity tells us about our ideals of beauty and the lengths to which people will go in order to become thin.
Along the way, Donnellan profiles the scientist whose contributions to the discovery of GLP-1 were overlooked, documents her fight for recognition while her colleagues were thrust into the limelight, and offers new insights into the ways that the food and beauty industries made billions while promoting unhealthy and unrealistic body image standards and accelerating the obesity crisis. She also provides firsthand accounts of several early Ozempic users and the transformative effect the drug has had on their weight loss journeys.
Off the Scales is an informative and entertaining study of the unexpected consequences of finally getting what weâve wanted for so long.